Equity Research Report: Oxygenta Pharmaceutical Limited
Date: February 5, 2026
Current Market Price (CMP): ₹58.50 – ₹60.00 (approx)
Market Cap: ~₹216 Cr – ₹226 Cr (Micro Cap)
Sector: Pharmaceuticals (API & Intermediates)
1️⃣ Business Model & Work
“Struggling API Manufacturer”
- Core Business: Oxygenta Pharmaceutical (formerly S.S. Organics) active pharmaceutical ingredients (APIs) aur intermediates manufacture karti hai. Ye bulk drugs banate hain jo medicines (formulations) banane me kaam aate hain.
- Product Portfolio:
- Commercial APIs: Pantoprazole Sodium (Acidity), Vildagliptin (Diabetes), Telmisartan (BP), Lacosamide (Epilepsy).
- Intermediates: Inke paas intermediates ki bhi range hai jo inhi medicines ke liye use hoti hai.
- Operations: Company ki manufacturing unit Telangana me based hai.
- Industry Role: Ye ek small-scale API supplier hai. Market me “Price Taker” hai, “Price Maker” nahi.
2️⃣ Industry & Sector Analysis
- Status: High Competition & Regulatory Pressure.
- Growth Drivers:
- China+1: Global pharma giants supply chain diversify kar rahe hain, jiska fayda Indian API makers ko mil raha hai.
- PLI Scheme: Govt ki schemes sector ko push kar rahi hain, lekin Oxygenta jaisi micro-cap companies ke liye scale ka issue rehta hai.
- Major Competitors: Divi’s Lab, Laurus Labs (Giants), aur hundreds of unorganized small players.
3️⃣ Latest Financial Performance (STRICT DATA)
Source: Exchange Filings / Screener.in (Latest Results: Q3 FY26 – Declared Feb 4, 2026)
⚠️ CRITICAL OBSERVATION: Company continues to be Loss-Making.
| Metric | Q3 FY26 (Dec ’25) | Q2 FY26 (Sep ’25) | Q3 FY25 (Dec ’24) | Trend |
| Revenue | ₹33.93 Cr | ₹14.30 Cr | ₹33.21 Cr | ▲ 137% QoQ (Seasonal/Lumpy) |
| Operating Profit | Loss (-₹4.08 Cr) | Loss | Loss | ⚠️ Persistent Operational Loss |
| Net Profit (PAT) | -₹4.84 Cr (Loss) | -₹3.93 Cr | -₹3.93 Cr | ▼ Loss Widened |
| EPS | -₹1.32 | -₹1.07 | -₹1.07 | Negative |
| Finance Cost | ₹1.39 Cr | — | ₹0.39 Cr | ▲ Debt Burden Increasing |
Key Financial Ratios:
- ROE: Negative (Loss making).
- Book Value: NEGATIVE (-₹6 to -₹9). Liabilities assets se zyada hain.
- Debt/Equity: Not Meaningful (due to negative equity).
- Operating Margin: Negative (-12% approx).
Analysis:
- Revenue Volatility: Revenue me QoQ 137% ka jump dikha hai, lekin YoY growth flat hai (~2%). Ye dikhata hai ki business stable nahi hai, order-based (lumpy) hai.
- Profitability Crisis: Revenue badhne ke bawajood company loss kam nahi kar paayi. Operating level par hi company paisa loose kar rahi hai (-12% Margin), jo business viability par sawal uthata hai.
- Interest Burden: Finance cost significant badh gayi hai (YoY ~3x), jo cash flow ko squeeze kar rahi hai.
4️⃣ Management & Shareholding (Latest Pattern)
Period: December 2025
| Category | Holding % | Trend (vs Last Qtr) |
| Promoters | 55.93% | ▲ Increased (Positive Sign) |
| FIIs | 0.00% | Nil |
| DIIs | 0.03% | Negligible |
| Public | 44.04% | High Retail Float |
- Promoter Action: Virupaksha Organics (Promoter entity) ne open market se stake khareed kar holding ~51% se badhakar ~56% kar li hai. Despite losses, promoters ka buying karna ek contrarian positive signal hai.
- Pledging: Data not explicitly alarming, but balance sheet stress is high.
5️⃣ Valuation (Latest Market Data)
- Current PE: Negative (Not Applicable).
- Price to Book (P/B): Negative. (Stock technically worthless book value par trade kar raha hai).
- Market Cap: ~₹216 Cr.
- EV/Sales: ~2.6x (Expensive for a loss-making company).
Peer Comparison:
- Oxygenta: Loss Making, Negative Net Worth.
- Standard Pharma Peers (Solara/Granules): Profitable with healthy margins.
Fair Value Approach:
Standard valuation models (PE/DCF) yahan fail hain kyunki company distress me hai. Valuation purely “Speculative” hai based on Promoter buying hope.
- Fundamental Value: ZERO (until operations turn profitable).
6️⃣ Future Growth Triggers (3–5 Years)
- Turnaround by Parent (Virupaksha Organics): Promoters (Virupaksha) khud ek chemical player hain. Unka stake badhana indicate karta hai ki wo Oxygenta ko restructure kar sakte hain ya merge kar sakte hain.
- Product Approval Pipeline: Company ke paas R&D me Dapagliflozin aur Sitagliptin jaise high-demand diabetes drugs hain. Agar inka commercial production scale par shuru hota hai, to revenue multiply ho sakta hai.
- Cost Optimization: Management suppliers ke saath adjustment aur identification process par kaam kar rahi hai taaki margins improve hon.
7️⃣ Present Situation (Current Outlook)
- Stock Phase: Speculative / High Risk Zone. Stock news aur operator driven zyada lagta hai.
- Q3 Reaction: Results kal (Feb 4) aaye hain aur loss badhne ki wajah se sentiment negative/weak reh sakta hai.
- Technicals: Stock “Oversold” zone me ho sakta hai, lekin fundamental support missing hai.
8️⃣ Risk & Red Flags (Must Read)
- ⚠️ Negative Net Worth: Company ki liabilities uske assets se zyada ho gayi hain. Ye Insolvency Risk indicate karta hai. Agar fresh funds nahi aaye, to company survive nahi kar payegi.
- Operating Losses: Core business (dawa bechna) se paisa nahi ban raha hai.
- Debt Spiral: Interest cost badhti ja rahi hai.
- Micro-Cap Volatility: Low liquidity aur high beta hone ke karan, stock me 10-20% swings common hain.
9️⃣ Final Verdict
- Summary: Oxygenta Pharmaceutical ek Deep Distress Asset hai. Fundamental metrics (Profit, Margins, Book Value) sabhi RED mein hain. Akela positive point Promoter Buying hai, jo shayad kisi internal restructuring ka sanket hai.
- Conservative Investors: STRICTLY AVOID. Capital wipe-out hone ka risk hai.
- Aggressive / Special Situation Investors: Watchlist Only. Abhi buy karna gambling hoga. Wait karein ki company kam se kam ek quarter Operating Profit (EBITDA Positive) post kare. Current price (₹60) financials ko justify nahi karta.
- Target: Downside towards ₹30-40 open hai agar turnaround fail hota hai. Upside capped hai jab tak loss kam na ho.
Recommendation: SELL / AVOID (High Risk of Capital Erosion)
Next Step for You: Would you like me to research Virupaksha Organics (the promoter company) to understand their financial health, as Oxygenta’s survival depends on them?